Dose Effect of a Plant Extract on Fatigue

January 14, 2020 updated by: PepsiCo Global R&D

Effects of Two Doses of a Plant Extract on Mental and Physical Fatigue

Test the short-term effects of the acute consumption of two separate beverages containing different concentrations of polyphenols, a beverage containing 75 mg of caffeine and a flavored placebo beverage on mental energy and physical performance

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Georgia
      • Athens, Georgia, United States, 30602
        • University of Georgia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 49 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18-49 years of age
  • Self-report of good health
  • Physical activity requirement: Recreationally active (exercise ≥3 times per week for >30 minutes per session; both cyclists and non-cyclists may enroll)

Exclusion Criteria:

  • Under the care of a physician
  • Visual impairment that cannot be corrected with glasses or contact lenses
  • Inability to perform high intensity exercise (defined perceptually as exercise that feels at least "hard" and this is usually quantified using the Borg 6 to 20 scale. High intensity cycling exercise is defined objectively as exercise causing a high heart rate, defined as a heart rate that is equal to or greater than 70% of heart rate reserve.)
  • Inability to adequately perform the cognitive tasks (i.e., cannot complete the task due to -inability to understand instructions or >50% incorrect responses)
  • Presence of current or chronic gastrointestinal, sleep or psychiatric disorder
  • Pregnant/lactating
  • Current smoker
  • Report illegal drug use
  • Report hypersensitivity to caffeine
  • Food allergies/intolerances/sensitivities (including coffee or related foods/beverages/products)
  • Current use of dietary supplements, or prescription medication except for oral contraceptives
  • Unwillingness to abstain from over the counter medications (e.g. NSAIDS, allergy medications) and caffeine/coffee/foods high in polyphenols for 12 hours prior to the study
  • Unwilling to refrain from consuming apple and grapefruit products on study days and 12 hours prior to test days.
  • Participation in another clinical trial within the past 30 days or participation in another PepsiCo trial in the past 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Flavored Beverage Mix 1
Flavored still beverage
Consume one beverage at the beginning of each visit of the cross-over sequence
Experimental: Flavored Beverage Mix 2
Flavored still beverage with polyphenols, concentration 1
Consume one beverage at the beginning of each visit of the cross-over sequence
Experimental: Flavored Beverage Mix 3
Flavored still beverage with polyphenols, concentration 2
Consume one beverage at the beginning of each visit of the cross-over sequence
Experimental: Flavored Beverage Mix 4
Flavored still beverage with caffeine
Consume one beverage at the beginning of each visit of the cross-over sequence

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective mental energy: Cognitive test battery
Time Frame: Baseline and 60 min post treatment
Changes in subjective measures of mental alertness and mental fatigue through computer administered cognitive test battery domains of short-term memory, attention and mood. Tasks are word presentation, word recognition, picture presentation, picture recognition, Cognitive Demand Battery (CDB) serial 3 and serial 7 subtraction, and Bakan task/Rapid Visual Information Processing (RVIP). Performance measures: % correct, % errors and response time in milliseconds.
Baseline and 60 min post treatment
Subjective mental energy: VAS for mental alertness
Time Frame: Baseline and 60 min post treatment
Changes in subjective ratings of mental alertness following computer administered cognitively fatiguing tasks. Visual Analog Scale (VAS) for mental alertness has the score range 0-100 (from not at all to extremely).
Baseline and 60 min post treatment
Subjective mental energy: VAS for motivation
Time Frame: Baseline and 60 min post treatment
Changes in subjective ratings of motivation following computer administered cognitively fatiguing tasks. Visual Analog Scale (VAS) for motivation has the score range 0-100 (from not at all to extremely).
Baseline and 60 min post treatment
Subjective mental energy: VAS for mental fatigue
Time Frame: Baseline and 60 min post treatment
Changes in subjective ratings of fatigue following computer administered cognitively fatiguing tasks. Visual Analog Scale (VAS) for fatigue has the score range 0-100 (from not at all to extremely).
Baseline and 60 min post treatment
Subjective mental and physical energy: VAS for mental and physical state and trait energy and fatigue (EFS State Scales)
Time Frame: Baseline and 60 min post treatment
Changes in subjective ratings of mental alertness, motivation and fatigue following computer administered cognitively fatiguing tasks. Mental and Physical State and Trait Energy and Fatigue Scales (EFS State Scales) consist of 12 VAS items to measure intensity of current feeling of physical energy and fatigue and mental energy and fatigue (3 sub-scales each). Score range: The 3 items from each sub-scale are summed and scores for each sub-scale range from 0-300 (none to strongest).
Baseline and 60 min post treatment
Subjective mental energy: VAS for mood
Time Frame: Baseline and 60 min post treatment
Changes in subjective ratings of mental alertness, motivation and fatigue following computer administered cognitively fatiguing tasks. The Bond-Lader test uses 16 Visual Analog Scales (VAS) to measure different aspects of mood, with score range 0-100 for each scale (from absence of feeling to presence of feeling).
Baseline and 60 min post treatment
Subjective mental energy: VAS for caffeine symptoms
Time Frame: Baseline and 60 min post treatment
Changes in subjective ratings of mental alertness, motivation and fatigue following computer administered cognitively fatiguing tasks. Caffeine symptoms are measured on paper using 8 Visual Analog Scales (VAS) with score range 0-100 (from not at all to extremely).
Baseline and 60 min post treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical performance
Time Frame: During the last 3 minutes of 23 min high intensity cycling exercise (10 x 1 min work intervals each followed by 1 min rest. No rest after final interval, 3 min max power from minutes 20-23.
Mean power output in a timed cycling trial following post-treatment cognitive test battery and caffeine symptom VAS.
During the last 3 minutes of 23 min high intensity cycling exercise (10 x 1 min work intervals each followed by 1 min rest. No rest after final interval, 3 min max power from minutes 20-23.
Physical Fatigue
Time Frame: After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
Subjective categorical scale, score range 0-7, higher score indicates greater feeling of physical fatigue
After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
Alertness
Time Frame: After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
Subjective categorical scale, score range 1-7, higher score indicates greater alertness meaning a greater feeling of energy
After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
Effort
Time Frame: After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
Subjective categorical scale, Borg Ratings of Perceived Exertion (RPE) measures perception of effort, score range 6-20. Higher score indicates greater effort. 17 or greater generally indicates maximal effort
After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
Quadriceps muscle pain
Time Frame: After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.
Subjective categorical scale with ratio-like properties, scale 0-10 with open-ended option for ratings greater than but proportional to 10. Higher scores indicate greater perception of pain in the quadriceps
After each of 10 1-minute high intensity cycling intervals separated by 1 min rest and at end of exercise.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Patrick J O'Connor, PhD, University of Georgia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 29, 2019

Primary Completion (Actual)

December 6, 2019

Study Completion (Actual)

December 6, 2019

Study Registration Dates

First Submitted

February 26, 2019

First Submitted That Met QC Criteria

March 8, 2019

First Posted (Actual)

March 11, 2019

Study Record Updates

Last Update Posted (Actual)

January 18, 2020

Last Update Submitted That Met QC Criteria

January 14, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

IPD will be kept securely at U. Georgia for several years and can be accessed upon request by contacting Dr. Pat O'Connor (poconnor@uga.edu)

IPD Sharing Time Frame

After publication

IPD Sharing Access Criteria

Open access, upon request

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Energy

Clinical Trials on Flavored beverage

Subscribe